Overview

Research

Education /
Student life

For examinees

Research

HOME

Research

Faculty Members

Faculty Members

<Back

Center for Advanced Education and Research in Pharmaceutical Sciences Clinical Pharmacology and Therapeutics

Maeda ShinichiroAssociate professor / Lecturer

After completing the master's course at the Graduate School of Pharmaceutical Sciences, Osaka University, I have been working as a pharmacist at Osaka University Hospital. After that, I returned to the Graduate School of Pharmaceutical Sciences as a practitioner teacher, and now I am mainly in charge of lectures on medical subjects, hospital practice training, and Pharm.D clinical practice training.
The role required of hospital pharmacists has expanded rapidly in recent years, and it is expected that everyone who graduates from Osaka University will play a leading role. I hope I can help you as much as possible through education and research.

Research theme

A study aimed at individualized and appropriate administration of immunosuppressive drugs using population pharmacokinetic analysis

Immunosuppressive therapy is essential after organ transplantation, and multidrug therapy is being performed, centered on calcineurin inhibitors. These drugs are characterized by a narrow therapeutic concentration range, drug interactions, and large individual differences in pharmacokinetics. We aim to provide personalized drug therapy to individual patients by searching for factors that influence pharmacokinetics using a technique called population pharmacokinetics analysis.

Research aimed at searching for factors that cause adverse events in molecular-targeted drugs

Since molecular-targeted drugs act specifically on the target site, they have been actively developed in recent years as drugs with high efficacy and few adverse events. However, as we have gained experience in clinical practice, class-specific adverse events of molecular-targeted drugs have become clear. We mainly use the patient medical records of Osaka University Hospital to clarify patients who are prone to these adverse events, and aim to maximize the therapeutic effect of their drug therapy.

Representative achievements

Sasano M, Ohno M, Fukuda Y, Nonen S, Hirobe S, Maeda S, Miwa Y, Yokoyama J, Nakayama H, Miyagawa S, Sawa Y, Fujio Y, Maeda M.
Verification of pharmacogenomics-based algorithms to predict warfarin maintenance dose using registered data of Japanese patients.
Eur J Clin Pharmacol 75(7): 901-911 (2019).

Kitayama K, Maeda S, Nakamura A, Katayama I, Wataya-Kaneda M.
Efficiency of sirolimus delivery to the skin is dependent on administration route and formulation. J Dermatol Sci 94(3): 350-353 (2019).

Shintani T, Higashisaka K, Maeda M, Hamada M, Tsuji R, Kurihara K, Kashiwagi Y, Sato A, Obana M, Yamamoto A, Kawasaki K, Lin Y, Kijima T, Kinehara Y, Miwa Y, Maeda S, Morii E, Kumanogoh A, Tsutsumi A, Nagatomo I, Fujio Y.
Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer.
Oncotarget 9(101): 37520-37533 (2018).

Sasabe T, Maeda S, Kishida K, Yamano M, Miwa Y, Sugiyama T.
The metabolism of methazolamide in immortalized human keratinocytes, HaCaT cells.
Drug Metabolism Letters 10(4): 295-305 (2016).

Furuta K, Yoshida Y, Ogura S, Kurahashi T, Kizu T, Maeda S, Egawa M, Chatani N, Nishida K, Nakaoka Y, Kiso S, Kamada Y, Takehara T.
Gab1 adaptor protein acts as a gatekeeper to balance hepatocyte death and proliferation during acetaminophen-induced liver injury in mice.
Hepatology 63(4): 1340-1355 (2016).

Maeda S, Miwa Y.
Multicomponent high-performance liquid chromatography/tandem mass spectrometry analysis of ten chemotherapeutic drugs in wipe samples.
J Chromatogr B 921-922, 43-48 (2013).

Maeda S, Miyawaki K, Matsumoto S, Oishi M, Miwa Y, Kurokawa N.
Evaluation of environmental contaminations and occupational exposures involved in preparation of chemotherapeutic drugs.
Yakugaku Zasshi 130 (6), 903-910 (2010).

Oishi M, Maeda S, Hashida N, Ohguro N, Tano Y, Kurokawa N.
Pharmacokinetic behavior of intravitreal triamcinolone acetonide prepared by a hospital pharmacy.
Jpn J Ophthalmol 52 (6), 489-492 (2008).

Oishi M, Maeda S, Nakamura A, Kurokawa N, Ohguro N, Tano Y.
Examination of purification methods and development of intravitreal injection of triamcinolone acetonide.
Jpn J Ophthalmol 49 (5), 384-387 (2005).